Correction to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2018; Lippincott Williams & Wilkins; Volume: 71; Issue: 6 Linguagem: Inglês
10.1161/hyp.0000000000000075
ISSN1524-4563
Tópico(s)Healthcare Systems and Public Health
ResumoHomeHypertensionVol. 71, No. 6Correction to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection to: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Originally published9 May 2018https://doi.org/10.1161/HYP.0000000000000075Hypertension. 2018;71:e136–e139This article corrects the following2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesIn the article by Whelton et al, “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” which published ahead of print on November 13, 2017, and appeared in the June 2018 issue of the journal (Hypertension. 2018;71:1269–1324. DOI: 10.1161/HYP.0000000000000066), several corrections were needed.On page 1269, in the author list, “FACC” has been removed after Dr. Giddings’ name.On page 1270, in the Table of Contents and on page 1295, the 9.5. heading read, “9.5. Peripheral Arterial Disease.” It has been updated to read, “9.5. Peripheral Artery Disease.” It has also been updated on page 1303 in Table 22 and on page 1304 in Table 23.On page 1276, in the footnote for Table 5, second paragraph, last sentence, the reference 3 citation has been removed from the end of the sentence.On page 1278, the heading “4.3. Ambulatory BP Monitoring” has been deleted. The heading “4.4. Masked and White Coat Hypertension” now reads, “4.3. Masked and White Coat Hypertension.”On page 1279, Figure 1, bottom row, needed the following changes:The third box from the left (“Masked Hypertension”) was labeled as Class IIb. It has been updated to Class IIa. The shading of the box has been updated also.The fourth box from the left (“Elevated BP”) was labeled as Class IIb. It has been updated to Class IIa. The shading of the box has been updated also.On page 1280, Figure 2, bottom row, the second box from the left read, “Continue current therapy (Class IIa).” It has been updated to read, “Continue current therapy”; the Class of Recommendation color has been removed.On page 1284, in Table 14, the text in the first column, last row read, “Angiogenesis inhibitor (e.g., bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenif).” It has been updated to read, “Angiogenesis inhibitor (eg, bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenib).”On page 1287, legend to Figure 4, the third sentence, read, “*Using the ACC/AHA Pooled Cohort Equations (57).” It has been updated to read, “*Using the ACC/AHA Pooled Cohort Equations.S8.1.2-14,S8.1.2-15”On page 1287, the section “8.1.3. Follow-Up After Initial BP Evaluation” recommendation table title read, “Recommendations for Follow-Up After Initial BP Elevation.” It has been updated to read, “Recommendations for Follow-Up After Initial BP Evaluation.”On pages 1288–1290, in “Table 18. Oral Antihypertensive Drugs,” the following updates have been made:In the “Primary agents” section, the first row “Thiazide or thiazide-type diuretics,” the “Metolazone” section, the “Usual Dose, Range (mg/d)*”column read, “2.5–10.” It has been updated to read, “2.5–5.”In the “Primary agents” section, the second row “ACE inhibitors,” the “Ramipril” section, the “Usual Dose, Range (mg/d)*”column read, “2.5–10.” It has been updated to read, “2.5–20.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Felodipine” section, the “Usual Dose, Range (mg/d)*”column read, “5–10.” It has been updated to read, “2.5–10.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nicardipine SR” section, the “Usual Dose, Range (mg/d)*”column read, “5–20.” It has been updated to read, “60–120.” The “Daily Frequency” column read, “1.” It has been updated to read, “2.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nifedipine LA” section, the “Usual Dose, Range (mg/d)*”column read, “60–120.” It has been updated to read, “30–90.”In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nisoldipine” section, the “Usual Dose, Range (mg/d)*”column read, “30–90.” It has been updated to read, “17–34.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Diltiazem SR” section has been removed.In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Diltiazem ER” section, the “Usual Dose, Range (mg/d)*”column read, “120–480.” It has been updated to read, “120–360.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil IR” section, the “Usual Dose, Range (mg/d)*”column read, “40–80.” It has been updated to read, “120–360.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil SR” section, the “Usual Dose, Range (mg/d)*”column read, “120–480.” It has been updated to read, “120–360.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil-delayed onset ER” section, the “Drug” column read, “Verapamil-delayed onset ER (various forms).” It has been updated to read, “Verapamil-delayed onset ER.”In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil-delayed onset ER” section, the “Usual Dose, Range (mg/d)*”column read, “100–480.” It has been updated to read, “100–300.”In the “Secondary agents” section, the first row “Diuretics—loop,” the “Bumetanide” section, the “Usual Dose, Range (mg/d)*”column read, “0.5–4.” It has been updated to read, “0.5–2.”In the “Secondary agents” section, the third row “Diuretics—aldosterone antagonists,” the “Eplerenone” section, the “Daily Frequency” column read, “12.” It has been updated to read, “1 or 2.”In the “Secondary agents” section, the fourth row “Beta blockers—cardioselective,” the “Atenolol” section, the “Daily Frequency” column read, “12.” It has been updated to read, “2.”In the “Secondary agents” section, the fourth row “Beta blockers—cardioselective,” the “Metoprolol tartrate” section, the “Usual Dose, Range (mg/d)*”column read, “100–400.” It has been updated to read, “100–200.”In the “Secondary agents” section, the sixth row “Beta blockers—noncardioselective,” the “Propranolol IR” section, the “Usual Dose, Range (mg/d)*”column read, “160–480.” It has been updated to read, “80–160.”In the “Secondary agents” section, the sixth row “Beta blockers—noncardioselective,” the “Propranolol LA” section, the “Usual Dose, Range (mg/d)*”column read, “80–320.” It has been updated to read, “80–160.”In the “Secondary agents” section, the seventh row “Beta blockers—intrinsic sympathomimetic activity,” the “Carteolol” section has been deleted.In the “Secondary agents” section, the tenth row “Alpha-1 blockers,” the “Doxazosin” section, the “Usual Dose, Range (mg/d)*”column read, “1–8.” It has been updated to read, “1–16.”In the “Secondary agents” section, the penultimate row, the “Class” column read, “Central alpha1-agonist and other centrally acting drugs.” It has been updated to read, “Central alpha2-agonist and other centrally acting drugs.”In the “Secondary agents” section, the last row “Direct vasodilators,” the “Hydralazine” section, the “Usual Dose, Range (mg/d)*”column read, “250–200.” It has been updated to read, “100–200.”On page 1291, the heading “8.3.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP” has been renumbered as “8.2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP.”On page 1295, Figure 9, fourth row, the first box on the left read, “Aim for BP <140/90 mm Hg (Class IIb).” It has been updated to read, “Aim for BP <130/80 mm Hg (Class IIb).”On page 1304, Table 23, in the “Specific comorbidities” section, the penultimate row “Secondary stroke prevention (lacunar)” has been deleted.On page 1304, in the “Presidents and Staff” section for the American Heart Association, Ms. Hundley’s title is updated to read, “Manager, Production and Operations.”On page 1310, in the References for section “8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension,” the following changes were made:A reference was added: “S8.1.2-14. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49–73.”Reference “14. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-45” has been renumbered as “S8.1.2-15.”On page 1317, in Appendix 1, for Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6 “Personal Research” read, “None.” It has been updated to read, “Daiichi Sankyo Inc†”On page 1318, in Appendix 1, for Dr. Ovbiagele, column 4, “Speakers Bureau,” read, “None.” It has been updated to read, “Boehringer Ingelheim Korea Ltd.”On page 1318, in Appendix 1, for Dr. Wright, column 4, “Speakers Bureau,” read, “None.” It has been updated to read, “Amgen†.”On page 1318, in the Appendix 1 footnotes, the first paragraph has been deleted. It read:This table represents the relationships of committee members with industry and other entities (RWI) that are considered relevant to this document. Although most ACC/AHA guideline writing committees are constituted such that no more than half the members may have relevant RWI for 1 year before and during development of the guideline, rules for the prevention guidelines require that no members have relevant RWI from 1 year before appointment until 1 year after publication of the guideline. Members’ RWI were reviewed and updated at all meetings and conference calls of the writing committee during the document development period. The complete ACC/AHA policy on RWI is available at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy.It has been updated with 2 new paragraphs to read:This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.On page 1318, in the Appendix 1 footnotes, “†Significant relationship.” has been added.In the Comprehensive RWI Data Supplement for the writing committee, the following updates have been made:For Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6, “Personal Research” read, “None.” It has been updated to read, “Daiichi Sankyo Inc*.”For Dr. Ovbiagele, column 4, “Speakers Bureau” read, “None.” It has been updated to read, “Boehringer Ingelheim Korea Ltd.”For Dr. Wright, column 4, “Speakers Bureau” read, “None.” It has been updated to read, “Amgen*.”These corrections have been made to the print version and the current online version of the article, which is available at http://hyper.ahajournals.org/lookup/doi/10.1161/HYP.0000000000000066. Previous Back to top Next FiguresReferencesRelatedDetailsCited By Thakkar A, Hailu T, Blumenthal R, Martin S, Harrington C, Yeh D, French K and Sharma G (2022) Cardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention, Current Atherosclerosis Reports, 10.1007/s11883-022-01026-6, 24:7, (493-507), Online publication date: 1-Jul-2022. Enciso-Muñoz J and Díaz-Barreiro L (2022) Medición de la presión arterial sistémica, Cardiovascular and Metabolic Science, 10.35366/105183, 33:S3, (183-189), . Naqvi I, Cheung Y, Strobino K, Li H, Tom S, Husaini Z, Williams O, Marshall R, Arcia A, Kronish I and Elkind M (2022) TASC (Telehealth After Stroke Care): a study protocol for a randomized controlled feasibility trial of telehealth-enabled multidisciplinary stroke care in an underserved urban setting, Pilot and Feasibility Studies, 10.1186/s40814-022-01025-z, 8:1, Online publication date: 1-Dec-2022. Brettler J, Giraldo Arcila G, Aumala T, Best A, Campbell N, Cyr S, Gamarra A, Jaffe M, De la Rosa M, Maldonado J, Ojeda C, Haughton M, Malcolm T, Perez V, Rodriguez G, Rosende A, Gonzalez Y, Wood P, Zuñiga E and Ordunez P (2022) Factores impulsores y métodos de puntuación para mejorar el control de la hipertensión en la práctica clínica de la atención primaria: recomendaciones del grupo de innovación de HEARTS en las Américas, Revista Panamericana de Salud Pública, 10.26633/RPSP.2022.56, 46, (1), Online publication date: 10-May-2022. Reshetnik A (2022) Nächtlicher Hypertonus, CardioVasc, 10.1007/s15027-022-3675-9, 22:3, (30-31), Online publication date: 1-Jun-2022. Borrayo-Sánchez G (2022) El sistema de salud mexicano y la hipertensión arterial, Cardiovascular and Metabolic Science, 10.35366/105194, 33:S3, (259-265), . Cappuccio F, Campbell N, He F, Jacobson M, MacGregor G, Antman E, Appel L, Arcand J, Blanco-Metzler A, Cook N, Guichon J, L’Abbè M, Lackland D, Lang T, McLean R, Miglinas M, Mitchell I, Sacks F, Sever P, Stampfer M, Strazzullo P, Sunman W, Webster J, Whelton P and Willett W (2022) Sodium and Health: Old Myths and a Controversy Based on Denial, Current Nutrition Reports, 10.1007/s13668-021-00383-z, 11:2, (172-184), Online publication date: 1-Jun-2022. Brettler J, Giraldo Arcila G, Aumala T, Best A, Campbell N, Cyr S, Gamarra A, Jaffe M, De la Rosa M, Maldonado J, Ojeda C, Haughton M, Malcolm T, Perez V, Rodriguez G, Rosende A, Gonzalez Y, Wood P, Zuniga E and Ordunez P (2022) Fatores impulsionadores e scorecards para melhorar o controle da hipertensão arterial na atenção primária: recomendações do Grupo de Inovação da Iniciativa HEARTS nas Américas, Revista Panamericana de Salud Pública, 10.26633/RPSP.2022.68, 46, (1), Online publication date: 10-May-2022. Chernatska O and Sibongumusa X (2021) 10-YEAR RISK ESTIMATION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN HYPERTENSIVE PATIENTS, Eastern Ukrainian Medical Journal, 10.21272/eumj.2021;9(2):145-150, 9:2, (145-150), . Singh Sidhu N and Kaur S (2021) Cerebrovascular Disease and Hypertension Cerebrovascular Diseases [Working Title], 10.5772/intechopen.101180 Mezhal F, Oulhaj A, Abdulle A, AlJunaibi A, Alnaeemi A, Ahmad A, Leinberger-Jabari A, Al Dhaheri A, Tuzcu E, AlZaabi E, Al-Maskari F, Alanouti F, Alameri F, Alsafar H, Alblooshi H, Alkaabi J, Wareth L, Aljaber M, Kazim M, Weitzman M, Al-Houqani M, Ali M, Oumeziane N, El-Shahawy O, Al-Rifai R, Scherman S, Shah S, Loney T, Almahmeed W, Idaghdour Y, Ahmed L and Ali R (2021) The interrelationship and accumulation of cardiometabolic risk factors amongst young adults in the United Arab Emirates: The UAE Healthy Future Study, Diabetology & Metabolic Syndrome, 10.1186/s13098-021-00758-w, 13:1, Online publication date: 1-Dec-2021. Zhang L, Shao F and Li L (2020) Association of Copper and Zinc Intake with Inflammatory Bowel Disease and Fecal Incontinence Symptoms: Evidence from the National Health and Nutrition Examination Survey, Biological Trace Element Research, 10.1007/s12011-020-02390-7, 199:7, (2543-2551), Online publication date: 1-Jul-2021. Hsu W, Kao Y, Chen M, Chiang H, Chen S, Lu M, Shia B and Hsieh K (2021) A reappraisal of the prevalence of pediatric hypertension through a nationwide database in Taiwan, Scientific Reports, 10.1038/s41598-021-84001-6, 11:1, Online publication date: 1-Dec-2021. Machado M, Barbosa T, Chrispino T, Junqueira das Neves F, Rodrigues G, Soares P, Nóbrega A and D Elia L (2021) Cardiovascular and Autonomic Responses after a Single Bout of Resistance Exercise in Men with Untreated Stage 2 Hypertension, International Journal of Hypertension, 10.1155/2021/6687948, 2021, (1-10), Online publication date: 29-Mar-2021. Fadol A (2021) Dyspnea: Common Side Effect, Clinical Journal of Oncology Nursing, 10.1188/21.CJON.S2.10-12, 25:6, (10-12), Online publication date: 1-Dec-2021. Wan J, Goodman D, Willems E, Freedland A, Norden-Krichmar T, Santorico S, Edwards K, Boerwinkle E, Buse J, DeFronzo R, Ehrmann D, Elbein S, Fujimoto W, Kahn S, Hanis C, Mulivor R, Beck J, Norris J, Alan Permutt M, Behn P, Raffel L and Robbins D (2021) Genome-wide association analysis of metabolic syndrome quantitative traits in the GENNID multiethnic family study, Diabetology & Metabolic Syndrome, 10.1186/s13098-021-00670-3, 13:1, Online publication date: 1-Dec-2021. Osei A, Khan R, Grandhi G, Boakye E, Obisesan O, Dzaye O and Blaha M (2021) Coronary Artery Calcium Measurement to Assist in Primary Prevention Decisions for Aspirin and Lipid-Lowering Therapies, Current Cardiovascular Imaging Reports, 10.1007/s12410-021-09561-7, 14:11, Online publication date: 1-Nov-2021. Corsino L and Velez-Rivera J (2021) Cardiovascular Disease Risk Factors in the Hispanic/Latino Population Cardiovascular Disease in Racial and Ethnic Minority Populations, 10.1007/978-3-030-81034-4_11, (123-145), . Yogalakshmee A, Manimekalai M and Devi S (2021) A STUDY ON CORRELATION BETWEEN SYSTEMIC HYPERTENSION IN COVID-19, INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 10.36106/ijsr/9602995, (82-84), Online publication date: 1-May-2021. Gao Y, Ren C, Li X, Yu W, Li S, Li H, Wang Y, Li D, Ren M and Ji X (2021) Ischemic Conditioning Ameliorated Hypertension and Vascular Remodeling of Spontaneously Hypertensive Rat via Inflammatory Regulation, Aging and disease, 10.14336/AD.2020.0320, 12:1, (116), . Gillette M, Taylor A, Butulija D, Kadiyala H and Jneid H (2020) Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare, Cardiovascular Drugs and Therapy, 10.1007/s10557-020-06976-0, 34:4, (579-584), Online publication date: 1-Aug-2020. Green D, Wang M, Krasin M, Davidoff A, Srivastava D, Jay D, Ness K, Shulkin B, Spunt S, Jones D, Lanctot J, Shelton K, Brennan R, Mulrooney D, Ehrhardt M, Gibson T, Kurt B, Robison L and Hudson M (2020) Long‐term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort Study, Pediatric Blood & Cancer, 10.1002/pbc.28271, 67:10, Online publication date: 1-Oct-2020. Hirawa N and Umemura S (2020) 高血圧治療ガイドライン2019, Nihon Naika Gakkai Zasshi, 10.2169/naika.109.778, 109:4, (778-783), Online publication date: 10-Apr-2020. Okada H (2020) 2. Strategic Application of Clinical Practice Guideline for CKD Management2．CKD対策における診療ガイドラインの戦略的意義, Nihon Naika Gakkai Zasshi, 10.2169/naika.109.93a, 109:Suppl, (93a-97a), Online publication date: 20-Feb-2020. Leal J, Galliano L and Del Vecchio F (2020) Effectiveness of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Hypertensive Patients: a Systematic Review and Meta-Analysis, Current Hypertension Reports, 10.1007/s11906-020-1030-z, 22:3, Online publication date: 1-Mar-2020. Rahman S, Islam S, Haque T, Kathak R and Ali N (2020) Association between serum liver enzymes and hypertension: a cross-sectional study in Bangladeshi adults, BMC Cardiovascular Disorders, 10.1186/s12872-020-01411-6, 20:1, Online publication date: 1-Dec-2020. Singh P, Sharma R and Singh J (2020) Study of Prescribing Pattern and Adverse Drug Reactions in Hypertensive Patients with Comorbidities as per JNC 8 Hypertension Guidelines in a Tertiary Care Hospital of Punjab, Journal of Evidence Based Medicine and Healthcare, 10.18410/jebmh/2020/204, 7:19, (931-937), Online publication date: 6-May-2020. Ren Q, Ma C, Wang J, Guo X and Ji L (2020) Prevalence of Albuminuria in Cardiology and Endocrinology Departments and Its Influencing Factors: A Multicenter, Real-World Evidence Study in China, International Journal of Hypertension, 10.1155/2020/1231593, 2020, (1-7), Online publication date: 5-May-2020. Son H, Ryu J, Go S, Yi Y, Kim K, Oh Y, Oh K and Chin H (2020) Association of ambulatory blood pressure monitoring with renal outcome in patients with chronic kidney disease, Kidney Research and Clinical Practice, 10.23876/j.krcp.19.103, 39:1, (70-80), Online publication date: 31-Mar-2020. Kintscher U (2020) Update Hypertonie: Ab wann und wie behandeln?, CME, 10.1007/s11298-020-7973-1, 17:6, (9-17), Online publication date: 1-Jun-2020. Teeäär T, Serg M, Paapstel K, Vähi M, Kals J, Cockcroft J, Zilmer M, Eha J and Kampus P (2020) Atenolol’s Inferior Ability to Reduce Central vs Peripheral Blood Pressure Can Be Explained by the Combination of Its Heart Rate-Dependent and Heart Rate-Independent Effects, International Journal of Hypertension, 10.1155/2020/4259187, 2020, (1-8), Online publication date: 27-Apr-2020. Kario K, Chirinos J, Townsend R, Weber M, Scuteri A, Avolio A, Hoshide S, Kabutoya T, Tomiyama H, Node K, Ohishi M, Ito S, Kishi T, Rakugi H, Li Y, Chen C, Park J and Wang J (2020) Systemic hemodynamic atherothrombotic syndrome (SHATS) – Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2019.11.002, 63:1, (22-32), Online publication date: 1-Jan-2020. POP D, DĂDÂRLAT-POP A, CISMARU G, ZDRENGHEA D and MUNTEANU C (2020) The control of cardiovascular risk factors – an essential component of the rehabilitation of patients with ischemic heart disease. What are the current targets?, Balneo Research Journal, 10.12680/balneo.2020.310:Vol.11, No1, (20-23), Online publication date: 20-Feb-2020. Birudaraju D, Cherukuri L and Budoff M (2020) Update on Hypertension and Adaptations for Treatment, Medical Journal of Southern California Clinicians, 10.38206/130103, (18-24), Online publication date: 31-May-2020. Jiang Y, Fan F, Jia J, Li J, Xia Y, Zhou J, Huo Y and Zhang Y (2020) Brachial-Ankle Pulse Wave Velocity Predicts New-Onset Hypertension and the Modifying Effect of Blood Pressure in a Chinese Community-Based Population, International Journal of Hypertension, 10.1155/2020/9075636, 2020, (1-7), Online publication date: 13-Apr-2020. Saxena T, Saxena A, Ali A and Saxena M (2019) Vasomotor Center? A Possible Role in the Treatment of Hypertension, Clinical Cardiology and Cardiovascular Medicine, 10.33805/2639.6807.124, (37-42), Online publication date: 16-Dec-2019. Kario K (2019) 3. Cutting Edge Treatment for Hypertension3．高血圧の最新治療, Nihon Naika Gakkai Zasshi, 10.2169/naika.108.514, 108:3, (514-526), Online publication date: 10-Mar-2019. Tirmenštajn-Janković B (2019) Pathophysiological mechanisms of cardiovascular disease in chronic kidney disease and possibilities of prevention, Timocki medicinski glasnik, 10.5937/tmg1904170T, 44:4, (170-183), . Schectman J (2019) Review: In adults, general health checks do not reduce all-cause, cardiovascular, or cancer mortality, Annals of Internal Medicine, 10.7326/ACPJ201905210-052, 170:10, (JC52), Online publication date: 21-May-2019. Nadler D and Poppas A (2019) Can Early Management of Hypertension by General Practitioners Improve Outcome?, US Cardiology Review, 10.15420/usc.2019.5.1, 13:1, (58-60), Online publication date: 12-Mar-2019. Choi W, Choi J, Oh J, Shin I and Yang J Effects of Remote Monitoring of Blood Pressure in Management of Urban Hypertensive Patients: A Systematic Review and Meta-Analysis, SSRN Electronic Journal, 10.2139/ssrn.3331453 Amadi C, Mbakwem A, Kushimo O, Ajuluchukwu J and Akinkunmi M (2019) Prevalence of positive chronic kidney Disease screening in professional male long haul drivers at risk of cardiovascular Disease in Lagos, Nigeria: a cross-section study, BMC Public Health, 10.1186/s12889-019-7328-6, 19:1, Online publication date: 1-Dec-2019. Pederson E, Dhaliwal G, Gupta A, Else T and Houchens N (2019) A Branching Algorithm, Journal of Hospital Medicine, 10.12788/jhm.3315, 14:11, (707-711), Online publication date: 1-Nov-2019. Rippe J (2019) Are We Ready to Practice Lifestyle Medicine?, The American Journal of Medicine, 10.1016/j.amjmed.2018.07.024, 132:1, (6-8), Online publication date: 1-Jan-2019. Makarem N, Shechter A, Carnethon M, Mullington J, Hall M and Abdalla M (2019) Sleep Duration and Blood Pressure: Recent Advances and Future Directions, Current Hypertension Reports, 10.1007/s11906-019-0938-7, 21:5, Online publication date: 1-May-2019. Marton-Popovici M (2020) Modern Management of Hypertensive Emergencies, Journal Of Cardiovascular Emergencies, 10.2478/jce-2019-0020, 5:4, (126-130), Online publication date: 1-Dec-2019., Online publication date: 1-Dec-2019. Pinashin E and Stern C (2020) Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older from the American College of Physicians and the American Academy of Family Physicians, Journal of Contemporary Pharmacy Practice, 10.37901/jcphp17-00017, 66:2, (50-54), Online publication date: 1-Jun-2019. (2018) Target blood pressure level in older patients with hypertension高齢者高血圧の血圧管理基準―SPRINT研究を考慮に入れて―, Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 10.3143/geriatrics.55.539, 55:4, (539-546), Online publication date: 25-Oct-2018. Nawata K and Kimura M (2018) Empirical Studies of Effects of High Blood Pressure on Medical Costs and Heart Disease: Is the 2017 ACC/AHA Guideline Supported by Enough Evidence?, Health, 10.4236/health.2018.1011115, 10:11, (1498-1519), . Hemingway H, Lyons R, Li Q, Buchan I, Ainsworth J, Pell J and Morris A A National Initiative in Data Science for Health: An Evaluation of the UK Farr Institute, SSRN Electronic Journal, 10.2139/ssrn.3312791 Leong X (2018) The Spice For Hypertension: Protective Role of Curcuma Longa, Biomedical and Pharmacology Journal, 10.13005/bpj/1555, 11:4, (1829-1840), Online publication date: 28-Dec-2018. Inriani I, Narmawan N and Abadi E (2021) Pengaruh Senam Prolanis Terhadap Penurunan Tekanan Darah Pada Penderita Hipertensi di Wilayah Pesisir Puskesmas Soropia, Health Information : Jurnal Penelitian, 10.36990/hijp.v13i1.232, 13:1 Zhang M, Shen Y, Shi J and Yu J (2021) MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.610561, 7 Tkacheva O, Kotovskaya Y, Runikhina N, Frolova E, Ostapenko V, Sharashkina N, Baranova E, Bulgakova S, Villevalde S, Duplyakov D, Ilnitskiy A, Kislyak O, Kobalava Z, Konradi A, Nedogoda S, Orlova Y, Pogosova N, Proshchaev K and Chumakova G (2021) Arterial hypertension and antihypertensive therapy in older patients. The agreed opinion of experts from the Russian Association of Gerontologists and Geriatricians, the Antihypertensive League, the National Society for Preventive Cardiology, Rational Pharmacotherapy in Cardiology, 10.20996/1819-6446-2021-07-01, 17:4, (642-661) Khojakuliev B, Orazgylyjov O, Khojageldiev T and Kurdova M (2020) PHARMACOEPIDEMIOLOGY OF USING OF ANTIHYPERTENSIVE DRUGS BY FAMILY PHYSICIANS, Eurasian heart journal, 10.38109/2225-1685-2020-3-94-99:3, (94-99) Yang Y, Zhu Y, Long Y, Liu H, Shan X, Feng X, Peng K and Ji F (2021) Withholding vs. Continuing Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Before Non-cardiac Surgery in Older Patients: Study Protocol for a Multicenter Randomized Controlled Trial, Frontiers in Medicine, 10.3389/fmed.2021.654700, 8 Gu C, Yan J, Zhao L, Wu G and Wang Y (2022) Regulation of Mitochondrial Dynamics by Aerobic Exercise in Cardiovascular Diseases, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.788505, 8 Gakova E, Kayumova M, Akimov A, Gakova А and Akimova E (2021) Association of blood pressure and coronary heart disease in women of an open population of a moderately urbanized city of Western Siberia, "Arterial’naya Gipertenziya" ("Arterial Hypertension"), 10.18705/1607-419X-2022-28-1-76-86, 28:1, (76-86) Li Z, Liu Q, Liu F, Hidru T, Tang Y, Cong T, Gao L, Yang X and Xia Y (2021) Nomogram to Predict Left Atrial Thrombus or Spontaneous Echo Contrast in Patients With Non-valvular Atrial Fibrillation, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.737551, 8 Sánchez G (2018) Cardiovascular risk reduction: Past, present and future in Mexico, Annals of Clinical Hypertension, 10.29328/journal.ach.1001010, (038-047) Wang Zi Wei, W and Pohorielov O (2020) Clinical characteristics of transient vision disorders and arterial hypertension., Medicni perspektivi (Medical perspectives), 10.26641/2307-0404.2020.1.200404, 25:1, (73-79) Podzolkov V, Pisarev M and Zateyshchikova D (2018) Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities, Russian Journal of Cardiology, 10.15829/1560-4071-2018-11-89-95:11, (89-95) Spirk D, Noll S, Burnier M, Rimoldi S, Noll G and Sudano I (2020) First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH), Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.00046, 7 Petrukhina I, Lebedev P, Gladunova E, Ryazanova T, Garanin A and Blinkova P (2022) The analysis of the consumption level of antihypertensive drugs and statins in a retail pharmacy of the Samara Region in 2015–2020, FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology, 10.17749/2070-4909/farmakoekonomika.2022.103, 15:1, (59-71) Lopina E and Libis R (2019) Achieved blood pressure level and target organ damage in post-stroke hypertensive patients, "Arterial’naya Gipertenziya" ("Arterial Hypertension"), 10.18705/1607-419X-2018-24-6-693-703, 24:6, (693-703) Gamble D, Brikinns B, Myint P and Bhattacharya S (2019) Hypertensive Disorders of Pregnancy and Subsequent Cardiovascular Disease: Current National and International Guidelines and the Need for Future Research, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2019.00055, 6 Ostroumova O, Polyakova O, Listratova A, Logunova N and Gorohova T (2022) Thiazide and thiazide-like diuretics: how to make the right choice?, Kardiologiia, 10.18087/cardio.2022.1.n1862, 62:1, (89-97) Chaulin A and Duplyakov D (2021) Cardiac troponins in hypertension: mechanisms of increase and diagnostic value, "Arterial’naya Gipertenziya" ("Arterial Hypertension"), 10.18705/1607-419X-2021-27-3-, 27:4, (390-401) Benjamim C, Porto A, Valenti V, Sobrinho A, Garner D, Gualano B and Bueno Júnior C (2022) Nitrate Derived From Beetroot Juice Lowers Blood Pressure in Patients With Arterial Hypertension: A Systematic Review and Meta-Analysis, Frontiers in Nutrition, 10.3389/fnut.2022.823039, 9 Liu X, Shen H, Chen M and Shao J (2021) Clinical Relevance of Vitamins and Carotenoids With Liver Steatosis and Fibrosis Detected by Transient Elastography in Adults, Frontiers in Nutrition, 10.3389/fnut.2021.760985, 8 See C, Tseng C, Lin W, Chao J, Kuo T and Wang M (2021) Seasonal Change in Home Blood Pressure Monitoring Is Associated With Renal Outcome and Mortality in Patients With Chronic Kidney Disease, Frontiers in Medicine, 10.3389/fmed.2021.672651, 8 Tereshchenko S, Ruksin V, Gaponova N, Tkacheva O, Duplyakov D and Skibitsky V (2021) Approaches to the treatment of uncontrolled hypertension. Place of the Physiotens®, Russian Journal of Cardiology, 10.15829/1560-4071-2021-4535, 26:6, (4535) Saatchi M, Mansournia M, Khalili D, Daroudi R and Yazdani K (2020) Estimation of Generalized Impact Fraction and Population Attributable Fraction of Hypertension Based on JNC-IV and 2017 ACC/AHA Guidelines for Cardiovascular Diseases Using Parametric G-Formula: Tehran Lipid and Glucose Study (TLGS), Risk Management and Healthcare Policy, 10.2147/RMHP.S265887, Volume 13, (1015-1028) Mengden T and Weisser B (2021) Monitoring of Treatment for Arterial Hypertension, Deutsches Ärzteblatt international, 10.3238/arztebl.m2021.0158 Chaulin A and Duplyakov D (2021) Cardiac troponins in hypertension: mechanisms of increase and diagnostic value, "Arterial’naya Gipertenziya" ("Arterial Hypertension"), 10.18705/1607-419X-2021-27-4-390-401, 27:4, (390-401) Song Y, Li J, István B, Xuan R, Wei S, Zhong G and Gu Y (2021) Current Evidence on Traditional Chinese Exercises for Quality of Life in Patients With Essential Hypertension: A Systematic Review and Meta-Analysis, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.627518, 7 Ojji D, Ale B, Shedul L, Umuerri E, Ejim E, Alikor C, Agunyenwa C, Njideofor U, Eze H and Ansa V (2021) The Effect of Nebivolol on Office Blood Pressure of Blacks Residing in Sub-Saharan Africa (A Pilot Study), Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.613917, 7 Mao Y, Hu W, Liu L and Liu Q (2022) Association Between Gestational Diabetes Mellitus and Future Risk of Kidney Stones, Frontiers in Public Health, 10.3389/fpubh.2022.843383, 10 Starchina Y and Sleptcova K (2021) Treatment of cognitive impairment in arterial hypertension, Neurology, Neuropsychiatry, Psychosomatics, 10.14412/2074-2711-2021-5-90-95, 13:5, (90-95) Trikha R, Greig D, Kelley B, Mamouei Z, Sekimura T, Cevallos N, Olson T, Chaudry A, Magyar C, Leisman D, Stavrakis A, Yeaman M and Bernthal N (2020) Inhibition of Angiotensin Converting Enzyme Impairs Anti-staphylococcal Immune Function in a Preclinical Model of Implant Infection, Frontiers in Immunology, 10.3389/fimmu.2020.01919, 11 Privalova E, Belenkov Y, Danilogorskaya Y, Zheleznykh E, Kozhevnikova M, Zektser V, Lishuta A and Ilgisonis I (2022) To study the dynamics of serum levels of vascular remodeling in patients with hypertension, including in combination with type 2 diabetes mellitus during 12‑month therapy with perindopril A, Kardiologiia, 10.18087/cardio.2022.1.n1890, 62:1, (24-31) Chou E, Cheung S, Maxwell H, Pham N, Khine M and Rinehart J (2021) Clinical Validation of a Soft Wireless Continuous Blood Pressure Sensor During Surgery, Frontiers in Digital Health, 10.3389/fdgth.2021.696606, 3 Sun J, Hua Y, Zou H, Qu Q, Yuan Y, Sun G, Sun W and Kong X (2021) Association Between Waist Circumference and the Prevalence of (Pre) Hypertension Among 27,894 US Adults, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.717257, 8 Related articles2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesPaul K. Whelton, et al. Hypertension. 2018;71:1269-1324 June 2018Vol 71, Issue 6 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/HYP.0000000000000075PMID: 29743246 Originally publishedMay 9, 2018 PDF download Advertisement
Referência(s)